article
The Chinese regulator, the State Food and Drug Administration (SFDA) has issued a notice banning the use of nimesulide, an anti-inflammatory drug made by Switzerland's Helsinn, for children under the age of 12, considering potential side-effects such as liver and kidney damage, reports the Xinhau news agency. The drug entered the Chinese markets in 1997. 23 May 2011